EUVIMEDOpdag EUVIMED
Crossref

Drug-Free Approach to Regulate Undruggable Proto-Oncogene MYC Using Biomimetic Porous Nanoparticles for Cancer Immunotherapy

Emilia Happonen iD, Yijing Dang, Jiajia Wang, Silja Saarela, Minna Sivonen, Mohammed Zakir iD, Milla-Iida Laari, Yiannis Constantinou, Konstantin Tamarov iD, Henri Hakkarainen iD, Ahmed Bisher Montaser iD, Henri Leinonen iD and 10 more

ACS Applied Materials & Interfaces · 2025-08-20 · 17 (33) · 46521-46534

DOI: 10.1021/acsami.5c05042 ↗

At a glance

Journal article in ACS Applied Materials & Interfaces, published online on 2025-08-11. Written by Emilia Happonen and 21 co-authors. Institution: Department of Technical Physics, University of Eastern Finland, 70210 Kuopio, Finland. Major MEDLINE topics: Nanoparticles, Proto-Oncogene Proteins c-myc, Immunotherapy, Biomimetic Materials. Cited 5 times so far (Crossref); 56 references. Funded by: Research Council of Finland, Sy?p?s??ti?, National Natural Science Foundation of China.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

A proto-oncogene MYC plays a crucial role in controlling immune response, but as of today, it is undruggable. Some MYC inhibitors are under testing; nevertheless, they have low efficacy and severe toxicity. Up to now, the use of a drug-free approach to regulate MYC has been rarely investigated. The present study aims to identify the potential of drug-free photothermal therapy (PTT) in regulating MYC. Herein, biomimetic black porous silicon (BPSi) nanoparticles (NPs) were prepared via a novel self-templated Na-K alloy reduction method and then coated with a cancer cell membrane and polyethylene glycol. These NPs have efficient photothermal conversion, good biocompatibility, and homotypic tumor targeting. The results indicated that BPSi-based PTT could efficiently regulate MYC by tuning temperatures. However, only PTT at 50 °C could successfully inhibit MYC, while PTT at 46 °C upregulated MYC. Mechanism studies revealed that MYC inhibition was achieved via the downregulation of 'MYC Targets V1', and MAPK and JAK-STAT signaling pathways were involved. Finally, tumor-targeted PTT activated robust cancer immunotherapy by MYC inhibition and efficiently prevented tumor growth without significant toxicity in vivo. The present study highlights the potential of a drug-free approach to regulate MYC for more potent cancer immunotherapy.

Subjects

MeSH terms (MEDLINE)

NanoparticlesProto-Oncogene Proteins c-mycImmunotherapyBiomimetic MaterialsNeoplasmsProto-Oncogene MasHumansAnimalsMicePorosityCell Line, TumorSiliconPhotothermal TherapyMice, Inbred BALB C

Author keywords

antitumor immune responsedrug-freephotothermal therapyporous silicon nanoparticlestumor immune microenvironment

Substances

Proto-Oncogene MasProto-Oncogene Proteins c-mycMAS1 protein, humanSiliconMYC protein, human

Authors and institutions

  • Department of Technical Physics, University of Eastern Finland, 70210 Kuopio, Finland.
  • School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200241, China.
  • Department of Environmental and Biological Sciences, University of Eastern Finland, 70210 Kuopio, Finland.
  • School of Pharmacy, University of Eastern Finland, 70210 Kuopio, Finland.
  • A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70210 Kuopio, Finland.
  • Cancer Cell Circuitry Laboratory, Translational Cancer Medicine, University of Helsinki, 00290 Helsinki, Finland.

ORCID profiles: Emilia Happonen, Mohammed Zakir, Konstantin Tamarov, Henri Hakkarainen, Ahmed Bisher Montaser, Henri Leinonen, Haijun Yu, Zhiai Xu, Vesa-Pekka Lehto, Wujun Xu

Funding

  • Research Council of Finland
  • Sy?p?s??ti?
  • National Natural Science Foundation of China
  • Suomen Kulttuurirahasto

Cite

APA

Happonen, E., Dang, Y., Wang, J., Saarela, S., Sivonen, M., Zakir, M., Laari, M. I., Constantinou, Y., Tamarov, K., Hakkarainen, H., Montaser, A. B., Leinonen, H., Küblbeck, J., Örd, T., Taipale, M., Kaikkonen, M., Liu, R., Klefström, J., Yu, H., …, & Xu, W. (2025). Drug-Free Approach to Regulate Undruggable Proto-Oncogene MYC Using Biomimetic Porous Nanoparticles for Cancer Immunotherapy. ACS Applied Materials & Interfaces, 17(33), 46521-46534. https://doi.org/10.1021/acsami.5c05042

Vancouver

Happonen E, Dang Y, Wang J, Saarela S, Sivonen M, Zakir M, et al. Drug-Free Approach to Regulate Undruggable Proto-Oncogene MYC Using Biomimetic Porous Nanoparticles for Cancer Immunotherapy. ACS Applied Materials & Interfaces. 2025;17(33):46521-46534. doi:10.1021/acsami.5c05042

BibTeX
@article{Happonen2025,
  author = {Happonen, Emilia and Dang, Yijing and Wang, Jiajia and Saarela, Silja and Sivonen, Minna and Zakir, Mohammed and Laari, Milla-Iida and Constantinou, Yiannis and Tamarov, Konstantin and Hakkarainen, Henri and Montaser, Ahmed Bisher and Leinonen, Henri and Küblbeck, Jenni and Örd, Tiit and Taipale, Mari and Kaikkonen, Minna and Liu, Ruixian and Klefström, Juha and Yu, Haijun and Xu, Zhiai and Lehto, Vesa-Pekka and Xu, Wujun},
  title = {Drug-Free Approach to Regulate Undruggable Proto-Oncogene MYC Using Biomimetic Porous Nanoparticles for Cancer Immunotherapy},
  journal = {ACS Applied Materials & Interfaces},
  year = {2025},
  volume = {17},
  number = {33},
  pages = {46521--46534},
  doi = {10.1021/acsami.5c05042}
}
Start for free →